Patent · US Active

Treatment of ectodermal dysplasia with EDA1 fusion proteins

US8501177B2 · kind B2 · utility

2Cited by

5References

21Claims

0Family size

Assignee

Topotarget Switzerland SA · CH

Inventors

Olivier Gaide · Lausanne, CH
Pascal Schneider · Épalinges, CH
Jurg Tschopp · Épalinges, CH

Key dates

Filing date	Apr 8, 2010
Grant date	Aug 6, 2013
Priority date	—
Expiry date	Nov 5, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.